L
Lyndra Therapeutics (Formerly Lyndra)
The first-ever oral, ultra-long-acting, sustained release therapies, which enables patients to take a pill once a week rather than daily
About Lyndra Therapeutics (Formerly Lyndra)
Lyndra is a healthcare startup that operates in the pharmaceutical industry, focusing on the development of innovative drug delivery systems. The company's primary product is the LYNX™ drug delivery platform, which aims to simplify medication regimens by allowing patients to take a week's worth of medicine in a single dose. This could potentially reduce the number of pills a patient needs to take from daily to weekly or even monthly, making it easier for patients to adhere to their medication schedules.
Lyndra's business model is based on the development and commercialization of its drug delivery platform. The company's revenue is likely generated through partnerships with pharmaceutical companies that wish to use the LYNX™ platform for their own drugs, as well as through the sale of its own proprietary drugs that utilize the platform.
The company serves a broad range of clients, including pharmaceutical companies looking for more efficient drug delivery methods, healthcare providers seeking to improve patient compliance with medication regimens, and patients who struggle with complex medication schedules.
Lyndra's team is composed of a diverse group of professionals, including engineers, designers, technologists, chemists, doctors, and nurses, all working together to reinvent medicine and create a healthier world.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Founded
- 2015
- Headquarters
- Watertown, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Dec 2023 | $101M | $404M | Sun Pharmaceutical Industries · Polaris Partners · Sarissa Capital Management | ↗ |
| SERIES DOther financing | Jun 2023 | $20M | $303M | Polaris Partners | ↗ |
Growth signals
Latest recorded traffic for Lyndra Therapeutics (Formerly Lyndra) is 1.5K monthly website visits, down 34.8% over the last three months. Lyndra Therapeutics (Formerly Lyndra)'s team declined 7.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
US Department of Health and Human Services
National Institutes of Health
Series A11 investors entered at this stage
Polaris Partners- HCHealthlink Capital
GF Securities
Quark Venture
Yonghua Capital
Suffolk Equity Partners
Partners HealthCare
HOPU Fund
Bill & Melinda Gates Foundation
Gilead Sciences
Invus
Series B and later8 investors entered at this stage
- AIAIG Investments
ImpactAssets
Limitless Ventures
Cavendish Impact Capital
Mass General Brigham Ventures- YPYipinhong Pharmaceutical
Sun Pharmaceutical Industries
Sarissa Capital Management
Other known investors1 additional known investor
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lyndra Therapeutics (Formerly Lyndra) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lyndra Therapeutics (Formerly Lyndra)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.